Serum levels of adiponectin are inversely correlated with adipose tissue mass and have been found to be decreased in obesity, as well as in insulin resistance, type 2 diabetes mellitus, and metabolic syndrome (MS) [2,6,7,8]. This evidence concerns the gene ADIPOQ and myeloid sarcoma.